Literature DB >> 18334710

Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.

Flora Vernooij1, A Peter M Heintz, Petronella O Witteveen, Margriet van der Heiden-van der Loo, Jan-Willem Coebergh, Yolanda van der Graaf.   

Abstract

BACKGROUND: There is much debate on the necessity of regionalization of ovarian cancer care. We investigated the association between hospital type and survival of patients with ovarian cancer in The Netherlands.
METHODS: A retrospective, population-based cohort study was performed on all Dutch patients diagnosed with ovarian cancer from January 1, 1996, through December 31, 2003. We used data from the Netherlands Cancer Registry that were linked to mortality data from the Statistics Netherlands database to obtain the date and cause of death. Five-year relative survival ratios, defined as the ratio of the observed survival in the patient population to the expected survival of women in the general population with the same age, were determined for the total population and for groups stratified by tumor stage and/or hospital type. The association between hospital type and disease-specific survival was analyzed by use of multivariable Cox regression analyses.
RESULTS: We analyzed data from 8621 women with epithelial ovarian cancer, of whom 3482 (40%) were treated in general hospitals, 3510 (41%) were treated in semispecialized hospitals, and 1557 (18%) were treated in specialized hospitals. Five-year relative overall survival ratios of patients treated in general, semispecialized, and specialized hospitals were 38.0% (95% confidence interval [CI] = 36.0% to 39.9%), 39.4% (95% CI = 37.5% to 41.4%), and 40.3% (95% CI = 37.4% to 43.1%), respectively; median survival of patients aged 50-75 years was 36 months (interquartile range [IQR] = 13 to >54 months), 37 months (IQR = 14 to >54 months), and 38 months (IQR = 15 to >55 months), respectively. Age and cancer stage were associated with the relationship between hospital type and ovarian cancer-specific survival but histologic tumor type, grade, year of diagnosis, and socioeconomic status were not. Among patients with early-stage ovarian cancer, treatment in semispecialized and specialized hospitals was associated with lower risks of ovarian cancer-specific mortality than treatment in general hospitals. Among patients with stage I-IIA disease who were aged 50-75 years, risk of ovarian cancer-specific mortality was 30% and 42% lower after treatment in semispecialized and specialized hospitals, respectively, than in general hospitals (for semispecialized hospitals, hazard ratio [HR] = 0.70, 95% CI = 0.53 to 0.93; for specialized hospitals, HR = 0.58, 95% CI = 0.38 to 0.87). Among patients with advanced ovarian cancer, hospital type was not associated with survival.
CONCLUSION: Hospital type was statistically significantly associated with survival among Dutch ovarian cancer patients with early-stage ovarian cancer: Patients who were treated in specialized and semispecialized hospitals survived longer than patients treated in general hospitals.

Entities:  

Mesh:

Year:  2008        PMID: 18334710     DOI: 10.1093/jnci/djn033

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.

Authors:  Daniel R Budman; Julia Tai; Anthony Calabro; Veena John
Journal:  Invest New Drugs       Date:  2010-06-09       Impact factor: 3.850

2.  Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer.

Authors:  Jason D Wright; Yongmei Huang; Alexander Melamed; Ana I Tergas; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Obstet Gynecol       Date:  2019-06       Impact factor: 7.661

3.  If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer.

Authors:  Inge T A Peters; Carolien van Haaften; J Baptist Trimbos
Journal:  J Gynecol Surg       Date:  2014-10-01

Review 4.  Centralisation of services for gynaecological cancer.

Authors:  Yin Ling Woo; Maria Kyrgiou; Andrew Bryant; Thomas Everett; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

5.  Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.

Authors:  Joan L Warren; Linda C Harlan; Edward L Trimble; Jennifer Stevens; Melvin Grimes; Kathleen A Cronin
Journal:  Gynecol Oncol       Date:  2017-03-31       Impact factor: 5.482

Review 6.  Interventions for the treatment of borderline ovarian tumours.

Authors:  Olusola Faluyi; Melanie Mackean; Charlie Gourley; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

7.  Epithelial ovarian carcinoma types and the coexistence of ovarian tumor conditions.

Authors:  Catharina C van Niekerk; Johan Bulten; José A A M van Dijck; André L M Verbeek
Journal:  ISRN Obstet Gynecol       Date:  2011-07-14

Review 8.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

9.  PrognoScan: a new database for meta-analysis of the prognostic value of genes.

Authors:  Hideaki Mizuno; Kunio Kitada; Kenta Nakai; Akinori Sarai
Journal:  BMC Med Genomics       Date:  2009-04-24       Impact factor: 3.063

10.  The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium.

Authors:  Catharina C van Niekerk; Johan Bulten; G Peter Vooijs; André L M Verbeek
Journal:  Obstet Gynecol Int       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.